On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.

On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.